Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKD-382
- Development stage
- Unknown
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CKD-382 is a small molecule drug under development by Chong Kun Dang Pharmaceutical for the treatment of gastroesophageal reflux disease (GERD) and potentially other digestive system disorders. It is currently in early-stage clinical trials, with Phase 1 studies evaluating its pharmacokinetics, pharmacodynamics, and safety in healthy subjects. The precise mechanism of action has not been publicly disclosed as of June 2025. The drug is being investigated primarily for oral administration[2][3][6].
- Brand names
- Esoduet
- Other names
- Esomeprazole + Sodium Bicarbonate Chong Kun DangEsomeprazole magnesium + Sodium bicarbonate
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on CKD-382.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CKD-382.